- |||||||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jun 3, 2024 P3, N=271, Active, not recruiting, Changes in ctDNA can occur rapidly and reflect changes in patients' clinical tumour responses (NCT02681523). Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
- |||||||||| Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Review, Journal, Metastases: A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer. (Pubmed Central) - May 29, 2024 Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025 Aim: This systematic literature review aims to summarize the efficacy/effectiveness of treatments, including eribulin (ERI)-based and anti-human epidermal growth factor receptor 2 (HER2) treatments in advanced/metastatic HER2+ breast cancer...Longer overall survival (OS) was associated with 1L and 2L treatment, and for 3L+ studies that included ERI, ERI or trastuzumab (Tmab)
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors. (Hall A; Poster Bd #: 303) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2129; P2 Although manageable, neutropenia emerged as a notable adverse effect. These findings underscore the potential of this combination as a therapeutic strategy for advanced solid tumors, warranting further clinical investigation.
- |||||||||| Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J, Votrient (pazopanib) / Novartis, BeiGene, Halaven (eribulin mesylate) / Eisai
Results of a randomized phase II trial of 2nd-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib: Japan Clinical Oncology Group study JCOG1802 (2ND-STEP). (Hall A; Poster Bd #: 477) - Apr 24, 2024 - Abstract #ASCO2024ASCO_759; Pazopanib showed the best PFS and OS as the second-line treatment for patients with advanced STS among trabectedin, eribulin, and pazopanib. A phase III trial comparing GD with pazopanib is planned as the next step.
- |||||||||| Halaven (eribulin mesylate) / Eisai, ML210 / University of Sydney
Journal: Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma. (Pubmed Central) - Apr 22, 2024 Taken together, our findings show firstly that eribulin triggers ferroptosis in OCCC and this effect occurs via the suppression of the Nrf2-HO-1 signaling pathway, SOD activity and the promotion of lipid peroxidation. These findings suggest that eribulin-induced ferroptosis is associated with its anti-tumor effect and also could be a potential therapeutic target in OCCC.
- |||||||||| Piqray (alpelisib) / Novartis, Herceptin (trastuzumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov) - Apr 9, 2024 P3, N=27, Active, not recruiting, Trial completion date: Mar 2024 --> Oct 2025 Recruiting --> Active, not recruiting | N=300 --> 27 | Trial completion date: Sep 2026 --> Nov 2024 | Trial primary completion date: Jun 2026 --> Nov 2024
- |||||||||| Halaven (eribulin mesylate) / Eisai
Journal, Metastases: Effects of Eribulin on the RNA Content of Extracellular Vesicles Released by Metastatic Breast Cancer Cells. (Pubmed Central) - Mar 31, 2024 Then, we performed differential expression analysis, weighted gene co-expression network analysis (WGCNA), functional enrichment analysis, and miRNA-target identification. Our findings demonstrate the possible involvement of EVs from eribulin-treated cells in the spread of chemoresistance, prompting the design of strategies that selectively target tumor EVs.
- |||||||||| Trodelvy (sacituzumab govitecan-hziy) / Gilead
Review, Journal, Metastases: Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2- Breast Cancer. (Pubmed Central) - Mar 26, 2024 Sacituzumab govitecan demonstrated an overall benefit in terms of health-related quality of life. Current evidence indicates that sacituzumab govitecan is an effective treatment option, with a generally manageable tolerability profile, for patients with pre-treated, unresectable locally advanced or metastatic HR+/HER2- breast cancer.
- |||||||||| 5-fluorouracil / Generic mfg.
Journal: Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) - Mar 25, 2024 Not yet recruiting --> Recruiting A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
- |||||||||| TQB2930 / Sino Biopharm
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - Mar 12, 2024 P1/2, N=154, Recruiting, Therefore, further investigation of eribulin-based treatment in larger randomized trials for patients with advanced TNBC is warranted. N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
- |||||||||| Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Mar 12, 2024 P2, N=30, Recruiting, N=89 --> 154 | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Mar 2025 --> Dec 2026 Trial completion date: May 2025 --> Aug 2027 | Trial primary completion date: Nov 2023 --> Jun 2027
|